<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

OX40 Agonists: Boosting Cancer Immunotherapy

Following our recent post covering the Tumor Necrosis Factor Superfamily of Ligands and Receptors, we’re going to take a closer look at specific family members important in immuno-oncology. First up is the OX40 receptor and its binding partner OX40-Ligand (OX40L).

Important Targets in T Cell Co-Stimulation

OX40 is now at the forefront of the field which has been called “T cell co-stimulation”. Immune co-stimulators work by providing the signal that promotes the expansion and proliferation of killer CD8 and helper CD4 T cells.

While immune checkpoint therapies are “releasing the brakes,” co-stimulators are “stepping on the gas.” Both mechanisms are required for a robust immune system response.

Receptor and Ligand Characteristic of the TNFR Superfamily

OX40 (also known as CD134, ACT35, and TNFRSF4) is a 50kD type 1 transmembrane glycoprotein. The extracellular N-terminal portion of OX40 is 191 amino acids, containing three complete and one truncated cysteine-rich domains (CRDs) which are characteristic of the Tumor Necrosis Factor Receptor (TNFR) superfamily. The intracellular region consists of 36 amino acids.

OX40L (also known as gp34, CD252, and TNFSF4) is a 34kD type II transmembrane glycoprotein. It is expressed as a trimer and has a TNF homology domain; therefore, it is structurally similar to other molecules of the TNF superfamily and has some sequence homology.

OX40 and OX40L Genes Clustered with Other Family Members

The gene for OX40 is clustered on human chromosome 1 (mouse chromosome 4) with several other TNFR family molecules e.g. TNFR2, 4-1BB, HVEM, CD30, GITR, and DR3. The OX40L gene is on human and mouse chromosome 1, clustered with genes for two other TNF family members, FasL and GITRL.

OX40 Ligand Binding Modulates T Cell Activation and T Cell Effector Function

The OX40 receptor is expressed primarily on CD8+ T cells, NK cells, NKT cells, and neutrophils. OX40L is expressed on dendritic cells (DCs), B cells, macrophages, and at sites of inflammation (e.g. activated endothelium).

OX40 is a co-stimulatory receptor not constitutively expressed on resting naïve T cells, instead it serves as a secondary co-stimulatory immune checkpoint molecule. OX40L is also not expressed on resting antigen presenting cells, but is present following their activation.

Binding of OX40 to its ligand modulates T cell activation and T cell effector function.

Targeting OX40 in Preclinical Studies: Improved Tumor Free Survival and Immune Memory Response

Preclinical studies have shown that using anti-OX40 mAbs and OX40L-Fc fusion proteins can increase antitumor immunity and improve tumor free survival (1,2). OX40 dependent antitumor immunity required the expansion of CD8 and CD4 T cells, with a proportion of mice showing evidence of a strong memory sufficient to provide resistance upon tumor re-challenge (3,4).

Treg Cell Effects – Both Depletion and Expansion Observed

Preclinical studies have also shown that OX40 agonists might exert their anticancer activity by depleting the number of FoxP3+ regulatory T (Treg) cells, which express high levels of OX40.

In mice, OX40 is constitutively expressed on Treg cells, which is in contrast to humans where expression is induced - there is low/absent expression on peripheral Treg cells, but higher OX40 expression on human Treg cells isolated from sites of inflammation (e.g. tumors).

However, others have observed Treg cell expansion (5,6), suggesting that anti-OX40 can push Treg cells in both directions, depending upon the context of stimulation and the cytokine environment.

Clinical Trials Ongoing Including Combination Therapy

Recently, Phase I monotherapy studies [NCT01644968] have been conducted with an OX40 agonist (9B12, mouse monoclonal anti-OX40 antibody) in patients with metastatic solid tumors. Promising results were observed, showing a strong bioactivity of the compound, although no antitumor responses were seen (7). 12 out of 30 patients showed regression of at least one metastatic lesion, and the agent was well tolerated with mild to moderate side effects.

In order to increase anti-OX40 effect, a variety of combinatory therapy strategies are being investigated.

Currently, agonistic OX40 monoclonal antibodies (e.g. MOXR0916, PF-04518600, MEDI0562, MEDI6469, and MEDI6383) are being evaluated in several Phase I/II clinical trials either as monotherapy or in combination with other immunomodulating agents:

  • Durvalumab (anti-PD-L1 antibody) [NCT02221960]
  • Tremelimumab (anti-CLTA-4 antibody)/rituximab (anti-CD20 antibody) [NCT02205333]
  • utomilumab (anti-CD137 antibody) [NCT02315066]
  • atezolizumab (anti-PD-L1 antibody)/bevacizumab (anti-VEGF-A antibody) [NCT02410512] (8).

OX40 Combination Regimens Expanding Immunotherapy Benefits

The use of OX40 targeted co-stimulatory agonistic antibodies with other anticancer approaches, including immunotherapy, are promising approaches to overcoming the suppressive tumor microenvironment and expanding the cohort of patients that benefit from immune mediated cancer therapies.

References and Further Reading:

  1. Linch SN et al. OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. Front Oncol. 2015;5: 34.
  2. Jensen SM et al. Signaling through OX40 enhances antitumor immunity. Semin Oncol. 2010;37(5): 524-32.
  3. Gough MJ et al. Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice. J Immunother. 2010;33(8): 798-809.
  4. Song A et al. Cooperation between CD4 and CD8 T cells for anti-tumor activity is enhanced by OX40 signals. Eur J Immunol. 2007;37(5): 1224-32.
  5. Ruby CE et al. Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right. J Immunol. 2009;183(8): 4853-7.
  6. Xiao X et al. New insights on OX40 in the control of T cell immunity and immune tolerance in vivo. J Immunol. 2012;188(2): 892-901.
  7. Curti BD et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res. 2013;73(24): 7189-7198.
  8. Aspeslagh S et al. Rationale for anti-OX40 cancer immunotherapy. Eur J Cancer. 2016;52: 50-66.

Related Posts